Filter results

Clinical Studies


Contact Us for the Latest Status

  • VALOR-HCM Trial: Mavacamten in HCM Patients Referred for SRT Rochester, Minn.

    The purpose of this study is to evaluate the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) and/or European Society of Cardiology (ESC) guidelines (i.e., guideline).

Closed for Enrollment